The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker.
 
Qing Zhou
Honoraria - AstraZeneca; BMS Brazil; Boehringer Ingelheim; Lilly O.; MSD; Pfizer; Roche; Sanofi
 
Lin Wu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Hengrui Pharmaceutical; Innovent Biologics; Lilly; Merck; MSD; Pfizer; Roche
 
Bo Jiang
No Relationships to Disclose
 
Yingying Du
No Relationships to Disclose
 
Buhai Wang
No Relationships to Disclose
 
Xiaohua Hu
No Relationships to Disclose
 
Yong He
No Relationships to Disclose
 
Mingfang Zhao
No Relationships to Disclose
 
Yu Yao
No Relationships to Disclose
 
Jiuwei Cui
No Relationships to Disclose
 
Xiaorong Dong
No Relationships to Disclose
 
Haibo Zhang
No Relationships to Disclose
 
Rui Ma
No Relationships to Disclose
 
Huijuan Wang
No Relationships to Disclose
 
Jian Zhang
No Relationships to Disclose
 
Jinjing Xia
Employment - I-Mab; Roche
 
Yanni Zhang
Employment - I-Mab
Stock and Other Ownership Interests - I-Mab
 
John W. Hayslip
Employment - I-Mab; Nektar
Stock and Other Ownership Interests - Abbvie; Nektar
Patents, Royalties, Other Intellectual Property - Abbvie
 
Andrew X. Zhu
Employment - I-Mab
Leadership - I-Mab
Stock and Other Ownership Interests - I-Mab
Consulting or Advisory Role - Bayer; Eisai; Exelixis; Lilly; Merck; Roche/Genentech; Sanofi
 
Yi-Long Wu
Honoraria - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)